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State of the Art
Appetite Stimulants Use in Cystic Fibrosis
Samya Z. Nasr, MD1* and Donna Drury, MSc, RD2
Summary. Cystic fibrosis (CF) is an autosomal recessive disease. It affectsmultiple bodyorgans.
The lungs and pancreas are the most affected which results in progressive lung damage and
pancreatic insufficiency.Due to thediseaseprocess,CFpatients require significantly higher caloric
intake than recommended for other individuals. The nutritional goal for CF patients is to achieve
normal growth and development and, once genetic potential is reached, to maintain good
nutritional status throughout life. Evidence has shown that lung function is closely associated with
nutritional status in CF and that nutritional status is an independent predictor of survival. Most CF
patients are on a high calorie diet to help achieve normal growth and development and maintain
good lung function. Inadequate caloric intake in CF can lead to malnutrition. Malnutrition in CF
requires careful, multidisciplinary history taking, physical exam, and overall patient/family
assessment. Only by determining the actual cause of the malnutrition can appropriate and safe
therapies be used to treat it. Appetite stimulants, although efficacious in treatingmalnutrition in CF,
should only be prescribed if decreased food intake secondary to inadequate appetite is the
principal cause of themalnutrition and all other contributing factors have been assessed, ruled-out
or treated. In this review, we attempted to summarize the use of several appetite stimulants used in
CFandother diseases to improve appetite andmaximize caloric intake. Pediatr Pulmonol. 2008;
43:209–219.  2008 Wiley-Liss, Inc.
Key words: cystic fibrosis; appetite stimulants; megestrol acetate; cyproheptadine
hydrochloride; dronabinol; antipsychotic drugs; antidepressants; recombi-
nant human growth hormone; anabolic androgenic steroids.
INTRODUCTION
The fundamental nutritional goal for cystic fibrosis
(CF) is to achieve normal growth and development and,
once genetic potential is reached, to maintain good
nutritional status throughout life. Evidence has shown
that lung function is closely associated with nutritional
status inCF1–3 and that nutritional status is an independent
predictor of survival.4 Despite this knowledge, a large
proportion of the CF population still is not able to
achieve this nutritional goal. Epidemiological studies
from the USA have revealed three times the expected
prevalence of CF patients below the 10th percentile for
height and weight.5
Good nutritional status is dependent on the consump-
tion of adequate nutrients, which is driven by complex,
inter-related factors such as physical hunger, appetite,
food-related behaviors, emotions, knowledge, and beliefs.
Table 1 focuses onmultiple issues possibly contributing to
poor appetite or poor food intake in CF. Some of these
factors are directly related toCFand others are not butmay
bemore prevalent in peoplewith CF because of the impact
of the disease or the treatments on overall well-being.
There are several phases to food intake. First, there is
the gastric motility phase which is mediated by the vagus
afferents. This is followed by the post absorptive phase
which is mediated by the duodenal release of cholecys-
tokinin (CCK). Other hormones that are released include
ghrelin, and peptide YY3 (PYY). CCK promotes satiety
and slows gastric emptying by contracting the pyloric
sphincter. Ghrelin signals hunger and PYY promotes
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satiety by inhibiting gut motility. Thirdly, there is the
metabolic phase which results in the release of glucose,
insulin, and leptin. Finally, the ileal phase results in the
inhibition of gastric motility by inhibiting neuropeptide Y
release from the brain.6–9
In order to understandmalnutrition in CF, each phase of
this process must be considered. Diagnosing the cause of
an individual’s malnutrition requires careful, multidisci-
plinary history taking, physical exam, and overall patient/
family assessment. Only by determining the actual cause
of the malnutrition can appropriate and safe therapies be
used to treat it. Table 2 provides a framework for this
process. Issues listed in the table should be addressed
thoroughly. If malnutrition persists, appetite stimulants
should be considered.
Appetite stimulants, although efficacious in treating
malnutrition in CF, should only be prescribed if decreas-
ed food intake secondary to inadequate appetite is the
principal cause of the malnutrition and all other contri-
buting factors have been assessed, ruled-out, or treated.
For example, if depression is the principle cause of poor
food intake in a person with CF, it would be appropriate to
consider consulting a psychologist or a psychiatrist. It is
important that physicians treating depression in CF are
aware of the secondary effects of different antidepressants
on appetite in order not to further exacerbate the problem.
If the only therapy provided is appetite stimulants, the
problem of poor appetite may be effectively reversed, but
the depression is still present and untreated. Similarly,
if poor GI motility is the primary cause of poor food
intake, increased intakes achieved by the use of appetite
stimulants may lead to the exacerbation of the GI
symptoms. In this case, motility agents may be equally
or more effective and the underlying problem, not just the
symptoms, would be treated. Clinically, many of these
issues may be inseparable and appetite stimulants may
need to be prescribed in concert with other treatments, but
the other issues should also receive the attention and
treatment they deserve.
In this review, we attempted to summarize the use of
several appetite stimulants used in CF patients and
patients with other chronic diseases to improve their
appetite and maximize their caloric intake.
MEGESTROL ACETATE (MA)
Megestrol acetate (MA) (Megace1) is a synthetic,
orally active derivative of progesterone. It is widely used
in treating advanced breast cancer.10 One of the side
effects of MA is appetite stimulation and weight gain.10
The mechanism of action has not been established. It has
been postulated that the effect is partly mediated by
neuropeptide Y, a potent central appetite stimulant.11 In
animalmodels,MA stimulates its synthesis, transport, and
release, which may contribute to its appetite-stimulating
effect.12 Another speculation of its mechanism of action is
that it is a potent inducer of adipocyte differentiation in
3T3-L1 cells in vitro, raising the possibility that it
stimulates the conversion of fibroblasts to adipocytes,
thereby blocking or reversing the effect of tumor necrosis
factor on lipocyte differentiation.13,14 It has been used
successfully as an appetite stimulant in adult patients
with cancer and acquired immunodeficiency syndrome
(AIDS).15–22 It also improved patients’ general sense of
well-being.19–21
MA has been used in CF to treat anorexia and weight
loss.23–25 In a case report, four patients, ages 10–
18.5 years, with severe CF lung disease, anorexia and





BMI body mass index
BWG body weight gain
APDs antipsychotic drugs
rhGH recombinant human growth hormone
LBM lean body mass
AAS anabolic androgenic steroids
TABLE 1— Issues Contributing to Poor Appetite or Poor Food Intake
CF related Can occur in people with CF
Acute illness, pulmonary exacerbation,
inflammation, increased cytokines
Poor gastric emptying and/or
gastroesphageal reflux
Depression, anxiety, stress or
sadness
Eating disorder or disordered
eating behaviors
DIOS (distal intestinal obstructive
syndrome) or constipation leading
to abdominal pain and nausea
Nasal polyps which may
impair taste or the ability to
eat and breathe comfortably
at the same time
Inflammatory bowel disease Appetite neuro-transmitter
abnormality (ghrelin, peptide Y,
leptin, insulin)
Avoidance of foods mistakenly thought
to be ’bad’ for CF (‘‘carbohydrates
causing CF-related Diabetes’’, ‘‘fats
causing abdominal pain’’, ‘‘milk/milk
products causing secretions’’ etc.).
Sinusitis which may be
associated with pain with







Burden of therapies on time and energy to prepare and eat nutritious foods Abdominal pain, bloating or other symptoms of malabsorption
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appetite and improve weight gain. Three of the four
patients received gastrostomy tube feedings, and all were
pancreatic insufficient. The dose was 400–800 mg daily
and duration of usewas 6–15months. Appetite improved,
with significant weight gain in all patients and an increase
in mean weight for age percentile from<5th percentile to
approximately 25th percentile after 6 months of therapy
was noted. Quality of life was also shown to improve.23
Side effects were not reported in this case report. A
randomized, double-blind, placebo-controlled, crossover
pilot trial ofMA in 12malnourished children with CFwas
conducted over a 12-week period, followed by a 12-week
washout period, then the alternative treatment.24 The age
range was 21 months to 10.4 years. Six patients didn’t
complete the study, three for reasons unrelated to the
study, two because of developing diabetes while receiving
MA, and one who developed glucose intolerance while
receiving the placebo. Weight Z-score, body fat, and
lean bodymass (LBM) increased, and pulmonary function
improved in patients givenMA. Therewas little change in
linear growth during MA therapy. Side effects included
glucosuria, insomnia, hyperactivity, and irritability.24
Another randomized, double-blind, placebo-controlled
study was conducted to evaluate the effects of MA on CF
patients.25 Seventeen patients age 6 years and above were
enrolled in the study. MA dose used was 7.5–15 mg/kg/
day. The study duration was 6 months. The treatment
group had significant increase in weight-for-age Z-score
and reached 100% of their ideal body weight within
3 months of initiating therapy. Weight gain included both
fat and fat-free mass as measured by dual energy X-ray
absorptiometry (DXA). Pulmonary function improved in
the treatment group compared to the placebo group.
Reversible adrenal suppression was observed in the
majority of patients who received MA. Some patients
suffered from insomnia and moodiness while on MA.25
We observed adrenal suppression, diabetes and insomnia
in patients treated with long term MA (unpublished
data). MA was also reported to cause testicular failure
in CF patients and impotence in HIV-infected patients,
along with its known glucocorticoid-like activity some-
times leading to Cushing Syndrome and adrenal insuffi-
ciency.17,26,27 A case report of osteoporosis associated
with MA use in cancer patients was also documented.28
TABLE 2— Work-Up Strategies for Malnutrition in Cystic Fibrosis
Symptoms Information, tests and possible intervention strategies
Appetite
Decreased food intake Diet history, food records
History of events leading to poor appetite:
. Temporal onset
. Symptoms at the time of onset
. Emotional/social/financial coexisting issues
. Behavioral issues around eating
Observe mealtime interactions
Early satiety Gastric motility study
Avoidance of high energy foods Body satisfaction, desired body weight, eating attitudes, purging
behaviors (i.e., non-compliance to enzymes to lose weight)
Absorption/digestion
Abdominal pain, gas, bloating, frequent, foul stools, visible oil loss 72 hr fecal fat coefficient of dietary fat intake
Enzyme history:
. List of foods or beverages with which enzymes are not taken,
. Information on when and how enzymes are taken
. Reported compliance to prescribed enzymes
Low intestinal pH resulting in poor enzyme bioactivity:
. Good compliance to enzymes reported and observed;
. Enzyme dose 1,000–2,500 IU lipase/kg/meal
. Minimal response to enzyme dose adjustments in recent past
. Acid suppression or acid blocker therapies may be beneficial
Stool mass palpitated Abdominal X-ray; DIOS history
Refractory symptoms Rule out other GI processes common in CF: bacterial overgrowth,
constipation, intussusception, CF-related liver disease, and/or the
co-existance of lactose intolerance, celiac disease, etc.
Metabolism
Growth failure or unintentional weight loss Oral glucose tolerance test to rule-out glucosuric energy losses
Increased respiratory symptoms leading to elevated energy
requirements
Aggressive respiratory and physio-therapies
Use of systemic and/or inhaled corticosteroids Linear height more affected than body weight or body mass index; bone
age delay
Hyponatremia Recurrent hyponatremia or hyponatremic dehydration
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CYPROHEPTADINE HYDROCHLORIDE (CH)
Cyproheptadine hydrochloride (CH) (Periactin1) is
a first-generation antihistamine which is both a hista-
mine and serotonin antagonist. It is also known to have
a secondary effect of appetite stimulation.29,30 The
mechanism of action is unknown but it is not due to
hypoglycemic induced hyperphagia, as evidenced by
normal glucose tolerance testing and normal insulin levels
during use. In addition, it is not due to an increase in
endogenous growth hormone (GH).29,30 It was found to
stimulate weight gain in normal, underweight adults.31
CHwas shown to be an effective appetite stimulant in two
studies of asthmatic children.29,32 It was also shown to
be an effective appetite stimulant in anorexia nervosa33
and tuberculosis.34 However, CH was not shown to be
effective in producing weight gain in advanced cancer
with cachexia.35–37 BothMAandCHwere studied inHIV
patients and were found to be beneficial.38
A 12-week, randomized, double-blind, controlled study
of CH versus placebo was conducted in 18 CF patients.39
The dose usedwas 4mgQID, and the duration of the study
was 3 months. Sixteen patients completed the study.
Subjects in the CH group showed significant increases in
weight, height, body mass index (BMI) percentiles, ideal
body weight/height, weight for age Z-scores, and fat and
fat-free mass versus the placebo group. There were no
differences in antibiotic use or spirometric measures
between the two groups.No significant side effects, except
transient mild sedation, occurred in the CH group and
patients’ acceptance and adherence were good.39 A
follow-up study was conducted to evaluate the long-term
use of CH.40 Sixteen CF patients enrolled and 12 com-
pleted a 9-month open-label trial following the comple-
tion of the double-blind study.40 Subjects who had
changed from placebo to CH gained weight significantly
over 3–6 months, and those continuing on CH generally
maintained previously gained weight over the duration of
the study. There were some improvements, not statisti-
cally significant, in selected spirometricmeasures and side
effects were mild.40 From these studies, CH seems to be
safe and well-tolerated. It has a modest positive effect on
weight in most subjects, and with most of the gain
occurring in the first few months of use.39,40
DRONABINOL (Marinol1)
Dronabinol (Marinol1) is an oral form of delta-9-
tetrahydrocannabinol dissolved in sesame oil in soft
gelatin capsules. It is the principal psychoactive substance
present in marijuana. It is utilized as an alternative to
smoked marijuana for AIDS wasting syndrome and
nausea following chemotherapy.41 An important gap in
the knowledge base about dronabinol has been an accurate
assessment of its abuse potential.41 The most common
reasons for medicinal use of marijuana in HIV/AIDS
are appetite stimulation, weight gain, sleep, relaxation,
depression, nausea, vomiting, pain, and combating
antiretroviral side effects.42,43 A number of studies cite
the use of marijuana for treatment of cancer-related
anorexia, nausea, vomiting, pain, andmood disorders.44,45
There is no evidence of abuse or diversion of dronabinol.
There is no street market or value for dronabinol.41
Furthermore, it doesn’t provide effects that are considered
desirable in a drug of abuse.41 The onset of action is slow
and gradual, its effects are dysphoric and unappealing.41,43
A long-term study (12 months) of dronabinol was
conducted in 94 late-stage AIDS patients who previously
participated in a 6-week double-blind placebo-controlled
study.46All patients received dronabinol orally at a dose of
2.5mg twice daily (90%) or 2.5 mg once daily (10%). The
long-termuse of dronabinol resulted in consistent increase
in appetite with trends toward weight stabilization and
modest weight gain in AIDS patients.46,47 In addition, the
data from this study suggested that it may be administered
long-term in this patient population without development
of tolerance to the therapeutic effect. Few patients
developed adverse events which were related to the
central nervous system, for example, anxiety, confusion,
euphoria, and somnolence.47
It has been proposed to administer dronabinol to CF
patients to alleviate malnutrition and help treat wasting,
especially with severe disease.48 It was utilized in 11 CF
patients with severe nutritional deficiencies who had
failed conventional interventions of nutritional counseling
and high calorie supplement. The average age of the
patients was 25.9 years (range 14–44 years), and the
averageweight at the start of the study was 96.6 lbs. Mean
FEV1 was 26% of predicted. Patients were treated on
average for 3 months (range 1–6 months). The starting
dose was 2.5 mg in all patients and maximum dose was
5 mg twice daily.49 Patients receiving dronabinol had a
significant improvement in weight during the treatment
period (P¼ 0.03), with average weight at the end of the
treatment period of 103.8 lbs. FEV1 was 26.5% of
predicted, which was not statistically significant. Side
effects noted during the study period were euphoria,
hallucinations, and lethargy; each side effect only
occurred in one patient. All side effects responded to
lowering the dosage. No patients stopped the medication
due to side effects.49
In conclusion, dronabinol is a safe and effective appetite
stimulant with potential effectiveness in CF.
ANTIPSYCHOTIC/ANTIDEPRESSANT AGENTS
Antipsychotic Drugs
Excessive body weight gain (BWG) is a common side
effect of some typical and atypical antipsychotic drugs
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(APDs).50 Weight gain is linked to a decreased metabolic
rate, increased caloric intake, and decreased physical
activity.51 It is generally believed that there are multiple
mechanisms by which APDs induceweight gain, but their
precise nature remains unknown. Weight gain as a
drug effect may be a multifactorial process, involving
serotonergic, histaminergic, and/or adrenergic neuro-
transmission.51 A new generation of agents, the atypical
APDs, represents an important progress in the treatment of
psychotic disorders. Atypical antipsychotics achieve their
therapeutic effects by modulating the activity of these
neural pathways. Weight gain as a side effect may also
be due to the blockade of certain receptors, for example,
5-HT2c, that modulate appetite and bodyweight.
52Weight
gain is dependent on the specific drug and individual
patient. The atypical antipsychotics vary in their propen-
sity to cause weight change with the long-term treatment.
The largest weight gains are associated with clozapine
and olanzapine, and the smallest with quetiapine and
ziprasidone.Risperidone is associatedwithmodestweight
gain that is not dose related.53 However, clozapine and
olanzapine appear to display a high propensity to induce
glucose dysregulation and dyslipidemia. Insulin secretion
is preserved and thus high serum insulin levels are
observed; there appears to be peripheral insulin resistance,
which leads to glucose intolerance and type 2 diabetes
mellitus (DM).50 Sudden BWG, insulin resistance,
increased appetite, and related endocrine changes also
may be involved in the development of glucose intoler-
ance and dyslipidemia in predisposed individuals.
Patients’ blood glucose and lipids should be monitored
before treatment and at regular intervals.50
The use of olanzapine in an 18-year-old femalewith CF
and severe body dysmorphism led to a significant increase
in body weight, possibly by stimulating appetite.54 This
observation led to a larger open-label trial of low dose
olanzapine therapy in a group of 12 adults with CF who
had previously been losing weight despite maximal
conventional therapy.54 Age range was 18–40 years, with
a mean age of 21 years. Mean FEV1 was 27.4% predicted.
Eleven of the 12 subjects were pancreatic insufficient, and
7 subjectswere on regular insulin therapy.Olanzapinewas
started at 5 mg daily (usual range in psychiatric practice is
10–20mg daily). Ten subjects continued olanzapine for at
least 6 months. In two subjects, biochemical evidence of
liver dysfunction was detected shortly after starting
therapy and led to discontinuation of treatment with
subsequent normalization of liver function. Four subjects
reported increased sleepiness which responded to adjust-
ment of the time of dosing. Six subjects reported an
increase in appetite. At baseline, mean (SD) BMI was
16.65 (1.01). After 6 months, BMI was 18.61 (2.01).
When compared to baseline, change inBMI after 6months
of therapywas statistically significant (P¼ 0.01,Wilcoxon
sign-rank test).54
Antidepressants
Psychological functioning has been assessed in both
children and adults with CF, but the results have been
variable. Some studies have reported relatively normal
adjustment in older adolescent and adult CF patients.55–61
However, other studies have suggested elevated levels of
psychosocial impairment, including anxiety, depression,
and eating disorders.62–65 Most of the second group of
studies were done earlier than the first group (in the 1960s
until early 1990s). That might be a reflection of the poorer
treatment options and the shortened life expectancy then.
Overall, adults with CF report relatively healthy psycho-
logical functioning.55 Better lung function and a strong
social support system predicted better psychological
functioning.55 The prevalence of psychological and
psychosocial dysfunction of people with CF is associated
with worsening disease severity and lack of social
support.55,66 Antidepressants have been used, in addition
to other psychosocial interventions, to treat depression in
CF patients.67
In addition, antidepressants have been used as appetite
stimulants. All antidepressants have side-effects, in-
cluding appetite dysregulation. The non-adrenergic and
specific serotonergic antidepressants block the 5-HT2C
receptor (one of the serotonin receptors). Blockage of this
receptor may lead to an increase in appetite.68 They also
block the 5-HT3 (another serotonin receptor) which is the
main site of action for nausea and occasional emesis.
These two symptoms are usually associated with de-
creased appetite and failure to gain adequate weight in
patients with severe CF disease.68
Mirtazapine (Remeron1) is a noradrenergic and spe-
cific serotonergic antidepressant (NaSSA). It also has an
antihistamine effect. Its tolerability and safety profile
reflects a unique pharmacological profile. It is well tolerat-
ed and showsparticular benefits over other antidepressants
in terms of antianxiolytic effects, sleep improvement, and
gastrointestinal side-effects. Its main side-effect is weight
gain.68
Mirtazapine has been used as an appetite stimulant in
malnourished CF patients.69,70 The first study was a pilot
study of five patients age 14–19 years with mean FEV1 of
41.4%with growth failure. They were started on 15 mg of
mirtazapine once a day. Patients were on the medication
for a mean of 96 days (range 29–142 days). All subjects
demonstrated an increase in weight (5.8 kg, P< 0.01),
body fat (13.9–21.8 kg, P< 0.01) and an increase in
weight gain velocity (3.9 before starting treatment vs.
27.4 kg/year after treatment, P< 0.05). All subjects re-
ported mild sedation, dry mouth, increased thirst and
increased appetite. None of the subjects felt these
symptoms justified stopping the medication.69
The second study was a retrospective study. Six patients
were enrolled. Age range was 10–17 years at the start of
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therapy. Doses ranged from 15 to 45 mg once daily.
Patients received an average of 14.2 months of therapy
(range 8–28 months). All patients had an increase in BMI
percentile for age (mean 10.3%,median 8%, and range 2–
25%). Adverse effects were limited to somnolence.70
RECOMBINANT HUMAN GROWTH
HORMONE (rhGH)
Growth hormone (rhGH) has been approved by
the Food and Drug Administration for use in treating
AIDS-associated wasting.71 GH is a potent anabolic agent
that has been used in the posttraumatic state to reduce
nitrogen loss.72 The nitrogen retention induced by GH is
associated with increased whole-body protein synthesis
and LBM as well.72 Human GH is a single polypeptide
chain composed of 191 amino acids (molecular weight
22 KD) and coded on chromosome 17.71 Secreted by the
somatotrophs of the anterior pituitary gland, GH promotes
protein synthesis and fat utilization and decreases glucose
oxidation.71 GH stimulates the production of insulin-like
growth factor (IGF-I) in the liver and other organs
(muscle, bone, adipose tissue).71
The recommended dosage of rhGH is 4–6 mg adminis-
tered by subcutaneous injection daily. It offers a more ex-
pensive alternative, approximately 10–15 times the cost,
to appetite stimulants such as MA and dronabinol.71,73
The adverse effects associated with rhGH therapy
include mild edema and arthralgias, carpal tunnel
syndrome, gynecomastia, insulin resistance, and glucose
intolerance. Nonetheless, treatment has generally been
well tolerated.74,75 In children, using rhGH for long-term
replacement can lead to irreversible adverse effects such
as slipped capital femoral epiphysis, acromegaly, and
leukemia.71
Previous studies have documented that patients withCF
have a delay in attainment of pubertal maturation.76 The
relationship between weight gain and linear growth was
done, and a poor correlationwas found between the two.77
This study concluded that nutritional supplementation
alone may not be the best means for improving short
stature in CF.77 GH stimulates accrual of linear height and
has been used to improve weight gain in chronic
illness.78,79
Several studies have documented the safety and efficacy
of GH in improving growth and clinical status in CF
patients.80–85 A 1 year randomized controlled trial to test
the effect of GH on the clinical status of CF children was
conducted.80 Nineteen prepubertal children were recruit-
ed. The GH treatment group had significantly greater
height, height velocity, weight, weight velocity, and
change in lean tissue mass. There was also significant
improvement in delta forced vital capacity (FVC) com-
pared with the year before the study; respiratory muscle
strength also improved. The number of hospitalizations
and outpatient intravenous antibiotic courses significantly
decreased.80 A multicenter, randomized, controlled trial
that included 61 prepubertal CF patients confirmed the
results of this study. The study duration was 1 year.81
Another study evaluated the mechanism of the anabolic
effect of rhGH in CF patients. It was also evaluated
whether glutamine (GLN) (which has shown improve-
ment of nitrogen balance in diseases associated with
severe stress and protein wasting when supplemented
orally) alone has a protein anabolic effect. It also
evaluated if the combination of GLN and rhGH is more
potent than either one alone.82 Nine undernourished or
short CF children were recruited. The study concluded
that in children with CF (1) oral GLN may not promote
protein gain in the fasting state; and (2) a short course of
rhGH has a potent anabolic effect that is mediated by
stimulation of protein synthesis and does not affect GLN
kinetics.82
GH was reported to enhance nutrition and growth in
CF children receiving enteral nutrition.83 A retrospective
study of GH use in pubertal CF adolescents suggested that
GH safely improved height, body weight, bone minera-
lization, and clinical status.84 GH was evaluated in eight
adult CF patients with mild or moderate pulmonary
disease. In this study, GH appears to improve weight and
body composition.85 In patients with severe pulmonary
disease, GH appears to stabilize loss of weight, bone and
muscle mass.85
A multicenter, randomized, double-blind, placebo-
controlled trial was conducted to evaluate the metabolic
and respiratory effects of GH in 63 CF children (bone age
8–18 years).86 BMI was<10 and/or weight<3 percentile
despite a high caloric intake (>120% RDA). Height and
growth velocity as well as growth factors (IGF1, IGFBP3)
increased significantly (P< 0.05). A significant effect on
weight gain was not observed. FEV1 both absolute and in
percent predicted didn’t change significantly with GH
treatment. The study concluded that GH therapy had
positive metabolic effects but didn’t improve lung
function in CF patients.86
ANABOLIC ANDROGENIC STEROIDS (AAS)
Since anabolic androgenic steroids (AAS) are deriva-
tives or structural modifications of the parent steroid
hormone, testosterone, they exhibit both anabolic and
androgenic activities.87 Anabolic effects are the promo-
tion of protein synthesis, nitrogen retention, and skeletal
muscle growth. Androgenic effects are the development
andmaintenance of primary and secondary sexual charac-
teristics in males. In females, androgenic effects are
evident as male pattern baldness, deepened voice, clitoro-
megaly, and growth of facial hair.87 Oxandrolone has
marked anabolic activity and few androgenic effects
(ratio 10:1), in comparison with testosterone and methyl-
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testosterone.88 It is a marked contrast with other oral AAS
that are metabolized extensively in the liver, oxandrolone
is relatively resistant to liver biotransformation. Approx-
imately 28%of it is excreted unchanged and unconjugated
in the urine.89 Oxandrolone is the only AAS that is US
FDA approved for restitution of weight loss after severe
trauma, extensive surgery, chronic infections, malnutri-
tion due to alcoholic cirrhosis, and Duchenne’s or
Becker’s muscular dystrophy.87 Statistically significant
improvements were reported in the areas of body
composition, recovery, muscle strength, and function,
and/or functional status.87 Oxandrolone is used in the
treatment of short stature due to Turner’s syndrome and
constitutional delay of growth and puberty.90,91 It is used
in acute catabolic disorders (e.g., burn injury and acute
multiple trauma).87 It is also used in chronic catabolic
disorders, for example, moderate to severe alcoholic
hepatitis, chronic obstructive pulmonary disease (COPD),
and Crohn’s disease.87 It has been used also in wasting
associated with HIV/AIDS.87 Adverse effects include
hepatic dysfunction (increased transaminase levels),
androgenic effects (alopecia, hirsutism, deep voice, and
clitoromegaly in girls and women).87 It has not been
studied in CF patients.
Prednisone has been studied in CF patients with mild-
moderate pulmonary disease to assess its effect on the
pulmonary inflammatory process.92 The study was a 4-
year, double-blind, placebo-controlled trial of alternate-
day prednisone (2 mg/kg) in 45 CF patients. The patients
in the prednisone group showed better growth and
pulmonary function and less morbidity compared with
those in the placebo group. No complications were
reported. Because of this observation, the United States
Cystic Fibrosis Foundation sponsored a multicenter,
double-blind, placebo-controlled trial of alternate-day
prednisone at a dose of 2mg/kg (high dose), 1mg/kg (low-
dose), or placebo every other day for 4 years. Two hundred
eighty five patients from 15 CF centers were enrolled in
the study from 1986 to 1987. An interim safety analysis
was done with mean duration in the study of 33.9 months
for the high-dose, 35.3 months for the low-dose, and
36.8 months for the placebo groups.93 This analysis
revealed increased frequency of cataracts, growth retar-
dation, and glucose abnormalities among patients in the
high-dose group.
In view of these results, it was recommended by the
study ombudsman and a special advisory panel that
the study drug be discontinued for all patients in the high-
dose prednisone group.93At the end of the study, therewas
significant improvement in the 1 mg group compared to
placebo in FVC (P< 0.025) in patients colonized with
Pseudomonas aeruginosa at baseline.94 In addition, there
was significant improvement in predicted forced expira-
tory volume in 1 sec (FEV1) in the 1 mg/kg group
compared to placebo (P< 0.02) and reduction in serum
IgGconcentrations (1mg/kg vs. placebo,P< 0.007; 2mg/
kg vs. placebo,P< 0.003). From 6months onward, height
Z-scores fell in the 2 mg/kg group compared to placebo
(P< 0.001). For the 1 mg/kg group, height Z-scores were
lower at 24 months. An excess of abnormalities in glucose
metabolismwas seen in the 2 mg/kg group compared with
the placebo group (P< 0.005).94
An evaluation of growth pattern, 6–7 years after
prednisone was discontinued in the previous study was
done retrospectively, through data collected from the CF
Foundation Patient Registry. The findings indicate that
growth suppression induced by long-term alternate-day
prednisone therapy was long-lasting in male children with
CF. The impact was particularly pronounced when
prednisone was taken prior to adolescence, in which case
final adult height appeared to be affected.95
Even though oxandrolone seems to be effective in
treating wasting and catabolic disorders in different
chronic disorders, long-term use of prednisone had the
opposite effect on growth in CF.
DISCUSSION
In view of the burden and demands on CF patient to
achieve normal growth and development, appetite stimu-
lants could be offered to help increase caloric intake. A list
of appetite stimulants discussed in this review is
summarized in Table 3. Several factors can lead to poor
appetite and food intake in CF patients. Some of these
factors are directly related to CF and others may be more
prevalent in CF. Appetite stimulants should be used only
after all other causes of weight loss and growth failure
have been excluded. They should be limited to patients in
whom conventional measures fail. Choice of appetite
stimulants should bemade according to physician, and CF
care team experience, patient’s age, severity of CF disease
and known side effects. In addition, the choice of appetite
stimulant should be discussed with the patient/family
prior to starting treatment. Side effects of the appetite
stimulant of choice should be monitored closely. An
algorithm of work up and intervention for CF patients at
nutritional risk is summarized in Table 4.
It has been documented that CF patients have demons-
trated an overall protein catabolism, even in non-acutely
ill subjects.96–98 Negative protein balance may contribute
to increased morbidity and mortality in CF by decreasing
body mass, and possibly by worsening immune func-
tion.99 An earlier study illustrated that reversal of protein
catabolism resulted in stabilization of pulmonary function
and decreased hospitalization rate.100 Chronic inflamma-
tion and protein catabolism are linked to high levels of
cytokines, particularly TNF-a in CF patients.98,101,102 In
one study of GH treatment of malnourished CF subjects
concluded that treatment with this agent resulted in mark-
ed decrease in TNF-a levels.98 The authors speculated that
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this may have been due to improved clinical status in this
treated group.
Appetite stimulants can be used prior to resorting to
invasive means to treat CF patients at nutritional risk.
However, the use of appetite stimulants and their benefits
in CF have been based on case reports and small studies.
More research is needed in this area to establish the
effect of improving nutritional status especially by adding
appetite stimulants, on the proinflammatory markers
(cytokines, TNF-a and others) and CF lung disease.
TABLE 4— Algorithm for Cystic Fibrosis Patients at Nutritional Risk (BMI Percentile 25% or Poor
Weight Gain for 3 Months)
TABLE 3— Summary of Appetite Stimulants in CF
Drug Dosage Side effects
Megestrol acetate (MA) 400–800 mg/day or 7.5–15 mg/kg/day orally Glucosuria, insomnia hyperactivity, irritability,
reversible adrenal suppression
Cyproheptadine hydrochloride (CH) 4 mg BID–QID or 0.5 mg/kg/day orally Transient mild sedation
Dronabinal (Marinol1) 2.5 mg qd–5 mg BID orally Anxiety, confusion, euphoria, somnolence
Antipsychotic
Olanzapine 5–20 mg qd orally Liver dysfunction, sleepiness, hyperglycemia
Risperidone 0.5–5 mg qd orally Glucose dysregulation, dyslipidemia
Antidepressents
Mirtazapine (Remeron1) 15–45 mg qd orally Mild sedation, dry mouth, somnolence
Recombinant human growth hormone
(rhGH)
4–6 mg qd SC injection Mild edema, arthralgia, carpal tunnel syndrome,
gynecomastia, insulin resistance, glucose
intolerance. In children, slipped capital femoral
epiphysis, acromegaly, leukemia
Anabolic androgenic steroids (AAS)
Oxandrolone 0.1 mg/kg/day BID, orally Hepatic dysfunction, androgenic effects in
females (alopecia, hirsutism, deep voice,
clitoromegaly), development of primary
and secondary sexual features in males. Not
studied in CF
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MA, CH, Dronabinol, and antidepressants have immuno-
modulatory effects. It would be interesting to study the
effects of these agents on the inflammatory markers as
well as appetite stimulation in large long terms studies.
Larger comparative studies with different appetite stimu-
lants in CF especially of longer durations and appropri-
ately powered would be beneficial.
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